stockportfolio.pro
Jazz Pharmaceuticals plc P/E Ratio 2009–2025
Jazz Pharmaceuticals plc (JAZZ) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -3.1%/yr over 16 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | — | — |
| FY 2024 | 14.24 | -29.4% |
| FY 2023 | 20.16 | — |
| FY 2022 | — | — |
| FY 2021 | — | — |
| FY 2020 | 39.11 | +138.2% |
| FY 2019 | 16.42 | -3.3% |
| FY 2018 | 16.98 | +0.4% |
| FY 2017 | 16.92 | -0.5% |
| FY 2016 | 17.01 | -36.7% |
| FY 2015 | 26.88 | -84.7% |
| FY 2014 | 176.05 | +388.3% |
| FY 2013 | 36.06 | +224.3% |
| FY 2012 | 11.12 | -23.2% |
| FY 2011 | 14.47 | -39.0% |
| FY 2010 | 23.71 | — |
| FY 2009 | — | — |
Source: Jazz Pharmaceuticals plc SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Jazz Pharmaceuticals plc
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeJazz Pharmaceuticals plc — frequently asked questions
What is Jazz Pharmaceuticals plc's price-to-earnings ratio?
Jazz Pharmaceuticals plc (JAZZ) reported price-to-earnings ratio of 14.24 for fiscal year 2024, per its SEC filings.
How has Jazz Pharmaceuticals plc's price-to-earnings ratio changed over time?
Between fiscal 2009 and 2025, JAZZ's price-to-earnings ratio declined at roughly 3.1% per year (compound annual rate), from 23.71 to 14.24.
Where does this data come from?
Figures are computed from Jazz Pharmaceuticals plc's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.